Evidence map›Paper›PMID 32963653›Full record

ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2020

A Retrospective Study on Amoxicillin Susceptibility in Severe

Pierre Danneels, Maria Concetta Postorino, Alessio Strazzulla, Nabil Belfeki, Aurelia Pitch, Frank Pourcine, Sebastien Jochmans, Vincent Dubée, Mehran Monchi, Sylvain Diamantis

Open access · goldAbstract read
In one paragraph

Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Global Antimicrobial Non-Susceptibility Patterns ofInfection and drug resistance · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Pierre DanneelsInfectious Diseases Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Maria Concetta PostorinoInfectious Diseases Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Alessio StrazzullaInfectious Diseases Unit, Groupe Hospitalier Sud Ile de France, Melun, France.ORCID https://orcid.org/0000-0003-0199-3449
Nabil BelfekiInternal Medicine Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Aurelia PitchMedical Biology Laboratory, Groupe Hospitalier Sud Ile de France, Melun, France.
Frank PourcineIntensive Care Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Sebastien JochmansIntensive Care Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Vincent DubéeCRCINA, Inserm, Paris, France.
Mehran MonchiIntensive Care Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Sylvain DiamantisInfectious Diseases Unit, Groupe Hospitalier Sud Ile de France, Melun, France.
Melun Hospital · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTreatment of

methodsA monocentric retrospective observational study including patients from 2008 to 2017 with severe pneumonia hospitalized in ICU. Evolution of amoxicillin and AMC susceptibility was showed. Characteristics of patients with Hi pneumonia were compared to characteristics of patients with

resultsOverall, 113 patients with Hi and 132 with Sp pneumonia were included. The percentages of AMC resistance among Hi strains decreased over the years (from 10% in 2008-2009 to 0% in 2016-2017) while resistance to amoxicillin remained stable at 20%. Also, percentages of Sp resistant strains for amoxicillin decreased over years (from 25% to 3%). Patients with Hi pneumonia experienced higher prevalence of bronchitis (18% vs. 8%,

conclusionsAmoxicillin resistance was stable over time, but no risk factors were detected. AMC resistance was extremely low, suggesting that AMC could be used for empiric treatment of Hi pneumonia, as well as other molecules, namely, cephalosporins. Patients with Hi pneumonia had more pulmonary comorbidities and severe diseases than patients with Sp pneumonia.

Identifiers

PMID32963653
PMCPMC7501540
OpenAlexW3084423626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.